| Contributors: |
Andersen, H.; Mantegazza, R.; Wang, J. J.; O'Brien, F.; Patra, K.; Howard, J. F.; Mazia, C. G.; Wilken, M.; Barroso, F.; Saba, J.; Rugiero, M.; Bettini, M.; Chaves, M.; Vidal, G.; Garcia, A. D.; Debleecker, J.; Van denAbeele, G.; Dekoning, K.; Demey, K.; Mercelis, R.; Mahieu, D.; Wagemaekers, L.; Vandamme, P.; Depreitere, A.; Schotte, C.; Smetcoren, C.; Stevens, O.; Vandaele, S.; Vandenbussche, N.; Vanhee, A.; Verjans, S.; Vynckier, J.; D'Hondt, A.; Tilkin, P.; AlvesdeSiqueira Carvalho, A.; Diasbrockhausen, I.; Feder, D.; Ambrosio, D.; Cesar, P.; Melo, A. P.; Martinsribeiro, R.; Rocha, R.; Bezerrarosa, B.; Veiga, T.; Dasilva, L. A.; Santosengel, M.; Goncalvesgeraldo, J.; daPenha AnaniasMorita, M.; Nogueiracoelho, E.; Paiva, G.; Pozo, M.; Prando, N.; Martinelitorres, D. D.; Butinhao, C. F.; Duran, G.; Gomes daSilva, T. C.; Otavio MaiaGoncalves, L.; Pazetto, L. E.; Fialho, T. A. S.; Renata CubasVolpe, L.; Souzaduca, L.; Ghellerfriedrich, M. A.; Guerreiro, A.; Mohr, H.; Pereiramartins, M.; daCruz Pacheco, D.; Ferreira, L.; Macagnan, A. P.; Pinto, G.; deCassia Santos, A.; Souza BulleOliveira, A.; Amaralandrade, A. C.; Annes, M.; Duarte Silva, L.; Cavalcantelino, V.; Pinto, W.; Assis, N.; Carrara, F.; Miranda, C.; Souza, I.; Fernandes, P.; Siddiqi, Z.; Phan, C.; Narayan, J.; Blackmore, D.; Mallon, A.; Roderus, R.; Watt, E.; Vohanka, S.; Bednarik, J.; Chmelikova, M.; Cierny, M.; Toncrova, S.; Junkerova, J.; Kurkova, B.; Reguliova, K.; Zapletalova, O.; Pitha, J.; Novakova, I.; Tyblova, M. |
| Description: |
To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. ; Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. Methods: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. Results: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. Conclusions: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624. |